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What Is the Correct Assignment on Enrolled 
Patients Receiving Various Doses of Medication 
in a Study Design?
TO THE EDITOR: In the October 2011 issue, Dickman et al
1 
pointed out that gastroesophageal reflux disease (GERD) pa-
tients presenting atypical reflux symptoms, disease duration/se-
verity, Helicobacter pylori infection and obesity etc. were likely re-
sponsible to the omeprazole treatment failure. Basically, the pur-
poses of GERD treatment are to heal erosive esophagitis (EE), to 
ameliorate reflux symptoms (mainly heartburn) and to prevent 
GERD complications.
2 However, the effectiveness of proton 
pump inhibitors (PPIs) to ameliorate heartburn is usually in-
ferior to healing of EE based on the standard dose. For example, 
non-erosive reflux disease (NERD) is somewhat difficult to treat 
compared to EE.
3,4 Treatment failure is a complex issue, and a lot 
of demographic factors in terms of female patients, weakly acidic 
reflux, bile reflux, visceral hypersensitivity, concomitant func-
tional bowel disorders, reduced physical and mental health-re-
lated quality of life, and inadequate interaction in the health serv-
ices etc. have been addressed as leading to the treatment 
failure.
2,3,5-7 In the literature, treatment failure is well defined as 
heartburn symptom not adequately responding to twice-daily 
PPI therapy.
2 Regarding this publication, several controversial 
issues need further clarification. First, the patient assignment in 
study design appears chaotic. According to the effectiveness of 
the number of omeprazole used, the authors had divided their en-
rolled subjects into three categories in terms of A (good to 1 tablet 
daily), B (failed to 1 tablet daily) and C (failed to 2 tablets daily). 
Since their GERD patients had been consecutively enrolled, it 
was unknown who should receive once or twice-daily omeprazole 
therapy during their assignment and the whole study period. If 
those patients were acknowledged as good to twice-daily treat-
ment as also defined by the literature,
2 what category should they 
be correctly fitted into? Second, endoscopic EE finding con-
stituted 18.0%, 51.3% and 30.4% among the group A, B and C 
patients, respectively. Alternatively, it means that the remainders 
would be either NERD or even Barrett’s esophagus (BE). Since 
the NERD patients are usually more often found than EE coun-
terparts among the epidemiological study,
8 their treatment result 
is very likely to mean that NERD patients did show a superior re-
sponse over EE undergoing PPI treatment.
Unfortunately, this observation is obviously contradictory to 
the literature, and the authors have not discussed what happened 
in this event. Finally, BE is not rare in Asia including Israel.
9,10 
This study should also include BE patients during their consec-
utive enrollment. It is also of interest to know what was the BE 
impact on PPI therapy in such a large-scaled GERD treatment 
study.
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